QUOTED. 19 August 2019. Michael Carrel.
AtriCure Inc. has closed a $300m structured deal to acquire SentreHEART Inc., the privately held developer of the Lariat percutaneous left atrial appendage (LAA) closure device. See what AtriCure CEO Michael Carrel said about it here.
"The [deal with SentreHEART] is significant and provides AtriCure with a complementary technology to not only diversify our portfolio, but also an opportunity to further leverage our existing commercial channel in the [electrophysiology] market. By adding the Lariat to their toolkit, physicians can offer a percutaneous epicardial left atrial appendage management solution." – Michael Carrel, CEO, AtriCure Inc.
Click here for a free trial of Medtech Insight